Skip to main content
  • Paul Scherrer Institut PSI
  • PSI Research, Labs & User Services

Digital User Office

  • Digital User Office
  • DE
  • EN
  • FR
Paul Scherrer Institut (PSI)
Search
Paul Scherrer Institut (PSI)

Hauptnavigation

  • Our ResearchOpen mainmenu item
    • Current topics from our research
    • Future Technologies
    • Energy and Climate
    • Health Innovation
    • Fundamentals of Nature
    • Large Research Facilities
    • Brochures
    • 5232 — The magazine of the Paul Scherrer Institute
    • Research Divisions & Labs (only english)
  • IndustryOpen mainmenu item
    • Overview
    • Technology Transfer
    • Expertise
    • Spin-off Companies
    • Park Innovaare
  • Proton TherapyOpen mainmenu item
    • Overview
    • Physician & Patient Information
  • CareerOpen mainmenu item
    • Overview
    • Job Opportunities
    • Working at PSI
    • Personnel Policy
    • Equal Opportunities, Diversity & Inclusion
    • Training and Further Education
    • Vocational Training
    • PSI Education Centre
    • Career Center
    • Support Program "PSI Career Return Program"
    • PSI-FELLOW/COFUND
  • Visit to PSIOpen mainmenu item
    • Overview
    • Visitor Centre psi forum
    • Schülerlabor iLab
    • Public Events
    • How to find us
  • About PSIOpen mainmenu item
    • PSI in brief
    • Strategy
    • Guiding principles
    • Facts and figures
    • Organisational structure
    • For the media
    • Suppliers and customers
    • Customers E-Billing
  • DE
  • EN
  • FR

Digital User Office (mobile)

  • Digital User Office

You are here:

  1. PSI Home
  2. Our Research
  3. Current topics from our research
  4. Paul Scherrer Institute and Apollo Health Ventures Launch Focal Biosciences

Secondary navigation

Our Research

  • Current topics from our research Expanded submenu item
    • Future Technologies
    • Energy and Climate
    • Health Innovation
    • Fundamentals of Nature
    • ESI Platform
    • Large research facilities
    • Project SLS 2.0
    • Topic Overview
    • Archive
  • 5232 – The magazine of the Paul Scherrer Institute
    • Contact
  • Brochures
  • Films
    • Virtual Tour
  • Social Media
    • PSI Community Guidelines
  • Media corner
    • Media Releases
11 October 2022

Paul Scherrer Institute and Apollo Health Ventures Launch Focal Biosciences

Media Releases Health Innovation Medical Science Radiopharmacy

The Paul Scherrer Institute PSI and Apollo Health Ventures have launched Focal Biosciences. The newly established biotech company aims to redefine the treatment of age-related diseases by reprogramming deregulated processes in cells that cause the detrimental processes underlying many serious diseases of aging that represent a significant health burden.

G. V. Shivashankar ist Leiter des Labors für Biologie im Nanobereich am Paul Scherrer Institut, Professor für Mechano-Genomik an der ETH Zürich und eine anerkannte Koryphäe im Bereich Mechano-Genomik mit umfassender Expertise in zellulärer Reprogrammierung.
G.V. Shivashankar is head of the Laboratory of Nanoscale Biology at Paul Scherrer Institute, Professor of Mechano-Genomics, ETH Zurich and a recognized leader in mechanogenomics with strong expertise in cellular reprogramming.
(Photo: Paul Scherrer Institute/Markus Fischer)

The Paul Scherrer Institute and Apollo Health Ventures will join their resources together with scientific founder G.V. Shivashankar who is head of the Laboratory of Nanoscale Biology at the Paul Scherrer Institute and Professor of Mechano-Genomics at the ETH Zurich, a recognized leader in mechanogenomics with strong expertise in cellular reprogramming. The newly founded entity will initially operate out of the Paul Scherrer Institute, the largest research institute for natural and engineering sciences in Switzerland that serves scientists around the world by accommodating highly complicated experiments in their industry-leading research facilities. Focal Biosciences thereby has access to PSI’s key infrastructure and expertise as part of Apollo's venture creation program, “Venture Labs” that sources leading science from scientists and labs in Europe and North America, based on its deep understanding of the biology of aging.

“Our investment approach is focused on identifying outstanding science to catalyze and build pioneering companies and taking an active role in their corporate evolution. We have watched the formation and maturation of the cellular reprogramming space for some time,” said Jan Adams, Venture Partner at Apollo Health Ventures. “We are confident that with the expertise and technologies developed by G.V. Shivashankar at PSI, Focal Biosciences can pursue a unique and innovative approach leveraging an advanced concept of cellular reprogramming, that will enable the development of a novel class of therapies.”

“We value Apollo Health Ventures’ and PSI’s commitment to our scientific vision of how to fundamentally change the treatment landscape for a variety of age-related diseases,” said G.V. Shivashankar. “I look forward to working with the expert team at Apollo to position Focal Biosciences for success and build a company that unlocks new approaches for patients with severe diseases.”

Advances in understanding the biology of aging coupled with emerging technologies have significantly increased pre-symptomatic detection of age-related damage and dysfunction, and paved the way for novel interventions. Cellular reprogramming in particular provides a novel approach of resetting damaged or dysfunctional cells to a healthy state, reversing disease mechanisms and stopping detrimental processes to transform the treatment landscape of age-related diseases.

Text based on a press release by Apollo Health Ventures

About Focal Biosciences
Focal Biosciences is redefining the treatment of age-related diseases by applying its deep scientific expertise in the mechanisms of cellular reprograming to reverse detrimental disease processes and restore health.

About Apollo Health Ventures
Apollo Health Ventures is a transatlantic venture capital firm specialized in developing and investing in data-driven biotechnology and health tech ventures. Apollo Health Ventures invests in game-changing companies at the seed or early stage and builds companies within the aging sector. Apollo’s team consists of entrepreneurs, seasoned biotech investors and scientists with remarkable track records in life science investments and venture creation.


About PSI

The Paul Scherrer Institute PSI develops, builds and operates large, complex research facilities and makes them available to the national and international research community. The institute's own key research priorities are in the fields of matter and materials, energy and environment and human health. PSI is committed to the training of future generations. Therefore about one quarter of our staff are post-docs, post-graduates or apprentices. Altogether PSI employs 2200 people, thus being the largest research institute in Switzerland. The annual budget amounts to approximately CHF 400 million. PSI is part of the ETH Domain, with the other members being the two Swiss Federal Institutes of Technology, ETH Zurich and EPFL Lausanne, as well as Eawag (Swiss Federal Institute of Aquatic Science and Technology), Empa (Swiss Federal Laboratories for Materials Science and Technology) and WSL (Swiss Federal Institute for Forest, Snow and Landscape Research). (Last updated in May 2021)

Contact

Prof. Dr. G.V. Shivashankar
Biology and Chemistry Division
Paul Scherrer Institute, Forschungsstrasse 111, 5232 Villigen PSI, Switzerland
Telephone:
+41 56 310 42 50, e-mail: gv.shivashankar@psi.ch [English]

Copyright

PSI provides image and/or video material free of charge for media coverage of the content of the above text. Use of this material for other purposes is not permitted. This also  includes the transfer of the image and video material into databases as well as sale by third parties.

Sidebar

01/2023

5232 — The magazine of the Paul Scherrer Institute

01/2023
View in issuu.com
Download
Subscribe to our magazine

Follow PSI

 Twitter
 LinkedIn
 Youtube
 Facebook
 Instagram

All social media channels


Visitor Centre psi forum

Experience research live


The iLab School Laboratory

Experience Science - Explore Research

top

Footer

Paul Scherrer Institut

Forschungsstrasse 111
5232 Villigen PSI
Switzerland

Telephone: +41 56 310 21 11
Telefax: +41 56 310 21 99

How to find us
Contact

Visitor Centre psi forum
School Lab iLab (in German)
Center for Proton Therapy
PSI Education Centre
PSI Guest House
PSI Gastronomie (in German)
psi forum shop

Service & Support

  • Phone Book
  • User Office
  • Accelerator Status
  • PSI Publications
  • Suppliers
  • E-Billing
  • Computing
  • Safety (in German)

Career

  • Working at PSI
  • Job Opportunities
  • Training and further education
  • Career Center
  • Vocational Training (in German)
  • PSI Education Center

For the media

  • PSI in brief
  • Facts and Figures
  • Media corner
  • Media Releases
  • Social Media

Follow us: Twitter (in English) LinkedIn Youtube Facebook Instagram Issuu RSS

Footer legal

  • Imprint
  • Terms and Conditions
  • Editors' login